- Home
- FMN vs UNCY Comparison
FMN vs UNCY Comparison
Compare FMN & UNCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FMN | UNCY |
|---|---|---|
| Founded | 2002 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.2M | 100.6M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | FMN | UNCY |
|---|---|---|
| Price | $10.52 | $3.74 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $28.40 |
| AVG Volume (30 Days) | 46.9K | ★ 1.0M |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | ★ 3.86% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $675,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $10,044.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.77 | $3.35 |
| 52 Week High | $11.76 | $8.74 |
Technical Indicators
Market Signals| Indicator | FMN | UNCY |
|---|---|---|
| Relative Strength Index (RSI) | 59.73 | 39.36 |
| Support Level | $9.77 | $3.35 |
| Resistance Level | $10.52 | $4.18 |
| Average True Range (ATR) | 0.12 | 0.26 |
| MACD | 0.05 | 0.04 |
| Stochastic Oscillator | 94.12 | 41.58 |
Price Performance
Historical ComparisonAbout FMN Federated Hermes Premier Municipal Income Fund
Federated Hermes Premier Municipal Income Fund is a United States-based diversified, closed-end management investment company. The investment objective of the fund is to provide current income exempt from federal income tax, including the federal alternative minimum tax by investing in long-term, tax exempt municipal bonds diversified among states, sectors and issuers. Its portfolio of investments comprises different sectors such as hospitals, toll road, senior care, airport, tobacco, and other sectors.
About UNCY Unicycive Therapeutics Inc.
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.